AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33819172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (testing for STIs and providing information on treatment facilities)
Number of subjects: 0
Study 33819172 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 0
Study 36152041 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 6919
Study 36152041 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 6919
Study 33143690 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV6/11/16/18 vaccine (vaccinated group)
Number of subjects: 2800
Study 33143690 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated (control group)
Number of subjects: 2800
Study 35656456 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 0
Study 35656456 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid (HA) injection
Number of subjects: 0
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg) with positive control (PC) diet
Number of subjects: 1512
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg) with negative control (NC) diet
Number of subjects: 1512
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive control (PC) without phytase
Number of subjects: 1512
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Coarse limestone with PC or NC diet
Number of subjects: 1512
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase (1,000 FYT/kg)
Number of subjects: 1512
Study 32111318 — intervention group
Group type: EXPERIMENTAL
Intervention: Phytase with coarse limestone
Number of subjects: 1512
Study 32111318 — intervention group
Group type: COMPARATOR
Intervention: Negative control (NC) without phytase
Number of subjects: 1512
Study 32264850 — intervention group
Group type: EXPERIMENTAL
Intervention: Fourier domain optical coherence tomography (OCT) measurements of macular thickness
Number of subjects: 116
Study 32264850 — intervention group
Group type: EXPERIMENTAL
Intervention: Age as a predictor
Number of subjects: 116
Study 34284006 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical Pudendal Nerve Stimulation (EPNS)
Number of subjects: 96
Study 34284006 — intervention group
Group type: COMPARATOR
Intervention: Pelvic Floor Muscle Training (PFMT) plus Transanal Electrical Stimulation (TES)
Number of subjects: 96
Study 32492096 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D and omega-3 fatty acid supplementation
Number of subjects: 0
Study 32492096 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35298223 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior (purchasing COVID-19-related items for others)
Number of subjects: 1623
Study 35298223 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosocial behavior (purchasing COVID-19-unrelated items for others)
Number of subjects: 1623
Study 35298223 — intervention group
Group type: COMPARATOR
Intervention: Proself behavior (purchasing COVID-19-related items for themselves)
Number of subjects: 1623
Study 35807803 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental milk-based formula (EF) containing five HMOs (5.75 g/L; 2′‐FL, 3‐FL, LNT, 3′‐SL and 6′‐SL)
Number of subjects: 363
Study 35807803 — intervention group
Group type: COMPARATOR
Intervention: Control milk-based formula (CF)
Number of subjects: 363
Study 35807803 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk (HM)
Number of subjects: 363
Study 35807803 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental milk-based formula (EF)
Number of subjects: 363
Study 32536111 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 17
Study 32536111 — intervention group
Group type: COMPARATOR
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 17
Study 35595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (factor-Xa inhibitor)
Number of subjects: 940
Study 35595781 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model including NT-proBNP
Number of subjects: 940
Study 34654496 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crowns
Number of subjects: 30
Study 34654496 — intervention group
Group type: COMPARATOR
Intervention: Glass fiber-reinforced composite crowns (GFRC)
Number of subjects: 30
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-step stair ascent test under dual task condition
Number of subjects: 38
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG test under dual task condition
Number of subjects: 38
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: TUG test under single task condition
Number of subjects: 38
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-m walking test under dual task condition
Number of subjects: 38
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-m walking test under single task condition
Number of subjects: 38
Study 32249513 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of falling and number of falls in the last year
Number of subjects: 38
Study 33108622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dociparstat sodium (DSTAT) added to standard of care
Number of subjects: 450
Study 33108622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 35337393 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic tongue exercises (SG)
Number of subjects: 40
Study 35337393 — intervention group
Group type: COMPARATOR
Intervention: No isotonic tongue exercises (CG)
Number of subjects: 40
Study 34852148 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (200,000 IU)
Number of subjects: 32
Study 34852148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 34856038 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodoform-based paste (Guedes-Pinto - GP)
Number of subjects: 61
Study 34856038 — intervention group
Group type: COMPARATOR
Intervention: Calcium hydroxide and iodoform paste (CaOH/Iodof paste; Vitapex®)
Number of subjects: 61
Study 35903280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise instructions from physical therapists for 30 min at baseline (week 0) and at week 4
Number of subjects: 36
Study 35903280 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise instructions from physical therapists
Number of subjects: 36
Study 33491327 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine 120 mg plus diphenhydramine 50 mg (DAW1033D)
Number of subjects: 10
Study 33491327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 32306076 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL + IL2
Number of subjects: 49
Study 32306076 — intervention group
Group type: COMPARATOR
Intervention: Abstention
Number of subjects: 49
Study 33175088 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 300
Study 33175088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 33615563 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-access pyeloplasty (laparoscopic, with or without robotic assistance)
Number of subjects: 116
Study 35412603 — intervention group
Group type: COMPARATOR
Intervention: Japanese encephalitis (JE) vaccine
Number of subjects: 61654
Study 34044124 — intervention group
Group type: EXPERIMENTAL
Intervention: adapted BWL (aBWL)
Number of subjects: 381
Study 34044124 — intervention group
Group type: EXPERIMENTAL
Intervention: aBWL + self‐determination theory (aBWL+SDT)
Number of subjects: 381
Study 34044124 — intervention group
Group type: EXPERIMENTAL
Intervention: aBWL + behavioral economics (aBWL+BE)
Number of subjects: 381
Study 34044124 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 381
Study 32767038 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaic arc dermabrasion (plasma exeresis technique)
Number of subjects: 45
Study 33339762 — intervention group
Group type: EXPERIMENTAL
Intervention: Community care setting (WIC)
Number of subjects: 129
Study 33339762 — intervention group
Group type: COMPARATOR
Intervention: Clinical care setting (primary care providers)
Number of subjects: 129
Study 33339762 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-for-length z scores
Number of subjects: 129
Study 33385738 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant asthma, rhinitis, and eczema
Number of subjects: 1103
Study 33385738 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma and rhinitis
Number of subjects: 1103
Study 33385738 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergic sensitization
Number of subjects: 1103
Study 32339370 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF) membrane
Number of subjects: 27
Study 32339370 — intervention group
Group type: COMPARATOR
Intervention: Deproteinized bovine bone mineral and resorbable collagen membrane
Number of subjects: 27
Study 35796651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (100 mg/day)
Number of subjects: 12
Study 35796651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 35796651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 12
Study 35796651 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin plus saline infusion
Number of subjects: 12
Study 35796651 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment + GIP(3‐30)NH2
Number of subjects: 12
Study 32079912 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 24
Study 32079912 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) with Caffeine (CAF)
Number of subjects: 24
Study 32079912 — intervention group
Group type: COMPARATOR
Intervention: High-Intensity Interval Training (HIIT) alone
Number of subjects: 24
Study 35437156 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtek™ Bulk Fill Posterior
Number of subjects: 120
Study 35437156 — intervention group
Group type: COMPARATOR
Intervention: Filtek™ Supreme XTE
Number of subjects: 120
Study 32940683 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparation for dialysis
Number of subjects: 0
Study 32940683 — intervention group
Group type: COMPARATOR
Intervention: Preparation for conservative care
Number of subjects: 0
Study 35460085 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic yogurt
Number of subjects: 90
Study 35460085 — intervention group
Group type: COMPARATOR
Intervention: Ordinary yogurt
Number of subjects: 90
Study 32083593 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycerin suppositories
Number of subjects: 34
Study 32083593 — intervention group
Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 34
Study 36050542 — intervention group
Group type: EXPERIMENTAL
Intervention: One planned, structured, telephone follow-up the day after discharge
Number of subjects: 525
Study 36050542 — intervention group
Group type: EXPERIMENTAL
Intervention: As B but with additional telephone follow-up once weekly for 6 weeks
Number of subjects: 525
Study 36050542 — intervention group
Group type: EXPERIMENTAL
Intervention: As C but with oriented coaching telephone follow-up on all occasions
Number of subjects: 525
Study 36050542 — intervention group
Group type: COMPARATOR
Intervention: No telephone follow-up (control group)
Number of subjects: 525
Study 34797217 — intervention group
Group type: EXPERIMENTAL
Intervention: High mindfulness
Number of subjects: 68
Study 34797217 — intervention group
Group type: EXPERIMENTAL
Intervention: Low mindfulness
Number of subjects: 68
Study 34797217 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress
Number of subjects: 68
Study 34797217 — intervention group
Group type: COMPARATOR
Intervention: No stress
Number of subjects: 68
Study 36398460 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight management programme
Number of subjects: 170
Study 36398460 — intervention group
Group type: COMPARATOR
Intervention: Best-practice care
Number of subjects: 170
Study 32897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital tranexamic acid (1 g) bolus and in-hospital tranexamic acid (1 g) 8-hour infusion (bolus maintenance group)
Number of subjects: 1280
Study 32897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-hospital tranexamic acid (2 g) bolus and in-hospital placebo 8-hour infusion (bolus only group)
Number of subjects: 1280
Study 32897344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (out-of-hospital and in-hospital)
Number of subjects: 1280
Study 32897344 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid groups (combined)
Number of subjects: 1280
Study 34772900 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction (LL-BFR) resistance training (20%-35% 1RM)
Number of subjects: 29
Study 34772900 — intervention group
Group type: COMPARATOR
Intervention: High-load (HL) resistance training (70%-85% 1RM)
Number of subjects: 29
Study 33978903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactics of Optimized Potential (TOP) program
Number of subjects: 180
Study 33978903 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Coherence (HC) program
Number of subjects: 180
Study 32323192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily (OD) or 15 mg OD if creatinine clearance was 30-49 mL/min
Number of subjects: 14264
Study 32323192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14264
Study 32323192 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg and 20 mg OD dosages
Number of subjects: 14264
Study 35112328 — intervention group
Group type: EXPERIMENTAL
Intervention: LY01008 (3 mg/kg)
Number of subjects: 102
Study 33397855 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml, administered every 15 days for 3 months (Group A)
Number of subjects: 60
Study 33397855 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of triamcinolone acetonide 10mg/ml in 1ml with injection hyaluronidase 1500IU in 2ml with injection 2% lidocaine 7ml plus oral colchicine 0.5mg twice daily for 3 months (Group B)
Number of subjects: 60
Study 36107416 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 1070
Study 36107416 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 1070
Study 32724076 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin therapy for 12 months
Number of subjects: 0
Study 32724076 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 0
Study 32724076 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP4 inhibition
Number of subjects: 0
Study 32724076 — intervention group
Group type: COMPARATOR
Intervention: High fat feeding
Number of subjects: 0
Study 35935797 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) in group B
Number of subjects: 362
Study 35935797 — intervention group
Group type: EXPERIMENTAL
Intervention: Flupentixol and melitracen (FM) + acid-suppressive therapy (AST) in group B
Number of subjects: 362
Study 35935797 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitors (PPIs) in group E
Number of subjects: 362
Study 35935797 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor antagonists (H2RAs) in group D
Number of subjects: 362
Study 35935797 — intervention group
Group type: COMPARATOR
Intervention: H2 receptor antagonists (H2RAs) in group A
Number of subjects: 362
Study 35935797 — intervention group
Group type: COMPARATOR
Intervention: Acid-suppressive therapy (AST) in group C
Number of subjects: 362
Study 33441418 — intervention group
Group type: EXPERIMENTAL
Intervention: U-TURN group (1-year supervised exercise and individualized dietary counseling)
Number of subjects: 98
Study 33441418 — intervention group
Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 98
Study 35772461 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy
Number of subjects: 0
Study 35772461 — intervention group
Group type: COMPARATOR
Intervention: No postoperative radiotherapy
Number of subjects: 0
Study 34033123 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent pregnancies after hyperemesis gravidarum
Number of subjects: 73
Study 34033123 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence of hyperemesis gravidarum in subsequent pregnancies
Number of subjects: 73
Study 34033123 — intervention group
Group type: EXPERIMENTAL
Intervention: Termination of pregnancy due to recurrent hyperemesis gravidarum
Number of subjects: 73
Study 34033123 — intervention group
Group type: EXPERIMENTAL
Intervention: Not getting pregnant again due to hyperemesis gravidarum
Number of subjects: 73
Study 34033123 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive factors for weight loss due to recurrent hyperemesis gravidarum
Number of subjects: 73
Study 32220194 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion group (temporary occlusion of the root of the splenic artery)
Number of subjects: 54
Study 32220194 — intervention group
Group type: COMPARATOR
Intervention: Non-occlusion group (direct dissection without occlusion)
Number of subjects: 54
Study 32220194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tumor diameter ≤3 cm)
Number of subjects: 54
Study 32220194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (tumor diameter >3 cm)
Number of subjects: 54
Study 32220194 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusion group
Number of subjects: 54
Study 32220194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 54
Study 32220194 — intervention group
Group type: COMPARATOR
Intervention: Non-occlusion group
Number of subjects: 54
Study 35722182 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg daily for 12 weeks
Number of subjects: 30
Study 35722182 — intervention group
Group type: COMPARATOR
Intervention: Untreated observation for 12 weeks
Number of subjects: 30
Study 34511288 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oxygen control with the CLiO2 algorithm
Number of subjects: 0
Study 34511288 — intervention group
Group type: COMPARATOR
Intervention: Manual control of oxygen titration
Number of subjects: 0
Study 34077887 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g EPA + 1.0 g DHA daily (n = 14)
Number of subjects: 32
Study 34077887 — intervention group
Group type: COMPARATOR
Intervention: Mineral oil daily (n = 18)
Number of subjects: 32
Study 34077887 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA+DHA group
Number of subjects: 32
Study 33999760 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified information letters
Number of subjects: 0
Study 33999760 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified information letters and questionnaire
Number of subjects: 0
Study 33999760 — intervention group
Group type: COMPARATOR
Intervention: Targeted information flyer
Number of subjects: 0
Study 33881774 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs and eye masks
Number of subjects: 100
Study 33881774 — intervention group
Group type: COMPARATOR
Intervention: Control (no earplugs and eye masks)
Number of subjects: 100
Study 33649058 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane administered by inhalation
Number of subjects: 0
Study 33649058 — intervention group
Group type: COMPARATOR
Intervention: Morphine administered intravenously
Number of subjects: 0
Study 33649058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (Methoxyflurane and Morphine)
Number of subjects: 0
Study 32195952 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 56
Study 32195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage chair therapy
Number of subjects: 56
Study 616631332 — intervention group
Group type: COMPARATOR
Intervention: Simulated sham lithium plasma concentrations
Number of subjects: 257
Study 616631332 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual lithium plasma concentrations in treatment arm
Number of subjects: 257
Study 34536349 — intervention group
Group type: EXPERIMENTAL
Intervention: BBIBP-CorV vaccine (2 ?g, 4 ?g, or 8 ?g)
Number of subjects: 1008
Study 34536349 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 1008
Study 32899074 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of intravenous dexamethasone
Number of subjects: 0
Study 32899074 — intervention group
Group type: COMPARATOR
Intervention: 1 dose of intravenous dexamethasone
Number of subjects: 0
Study 32899074 — intervention group
Group type: COMPARATOR
Intervention: 2 doses of intravenous dexamethasone
Number of subjects: 0
Study 34842957 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-QUAL v1 tool for evaluating prostate MRI quality
Number of subjects: 0
Study 34842957 — intervention group
Group type: EXPERIMENTAL
Intervention: PI-QUAL tool development
Number of subjects: 0
Study 34536763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective sensory nerve blockade (SSNB)
Number of subjects: 72
Study 34536763 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative periarticular infiltration (PAI)
Number of subjects: 72
Study 36109038 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care (MIC guided)
Number of subjects: 64
Study 36109038 — intervention group
Group type: EXPERIMENTAL
Intervention: MBEC-guided antibiotic regimen
Number of subjects: 64
Study 32241319 — intervention group
Group type: EXPERIMENTAL
Intervention: Choice-enhancing language ('the choice is yours')
Number of subjects: 174
Study 32241319 — intervention group
Group type: COMPARATOR
Intervention: Choice-restricting language ('you must')
Number of subjects: 174
Study 32353246 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 150 mg
Number of subjects: 476
Study 32353246 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 476
Study 35954320 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm A (treatment group)
Number of subjects: 306
Study 35954320 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm B (treatment group)
Number of subjects: 306
Study 33184097 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone plus prednisone (AAP)
Number of subjects: 736
Study 33184097 — intervention group
Group type: COMPARATOR
Intervention: Prednisone
Number of subjects: 736